Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot?
Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the ongoing layoffs. Despite the downsizing, there is movement. Here are some of the latest comings and goings. Recognize anyone?
And here is our regular feature in which we highlight a different person each week. This time around, we note that Endo International says Rajiv De Silva stepped down as chief executive officer and board member. His departure comes a year after completing the acquisition of Par Pharmaceuticals. Paul Campanelli, who is the new chief executive, previously headed Par before running Endo’s generic and over-the-counter business after the deal closed.
GlaxoSmithKline tapped Emma Walmsley to succeed Andrew Witty as chief executive officer;
Nexus BioPharma hired Helen Stefanovic as director of regulatory affairs;
EpiThany hired David Poston as chief operating officer;
Enumeral Biomedical hired Wael Fayad as chief executive officer and president;
uniQure says that Daniel Soland resigned as chief executive officer;
uniQure named Matthew Kapusta as interim chief executive officer;
Cure Forward hired Frank Ingari as chief executive officer;
aTyr Pharma hired David King as senior vice president, research;
Lannett says that Mahendra Dedhiya resigned as chief of scientific affairs;
10x Genomics hired John Pouk as chief commercial officer;
C4 Therapeutics promoted Andrea Armstrong to chief administrative officer;
Kleo Pharmaceuticals named Dr. David Spiegel as chief executive officer;
Kleo Pharmaceuticals named Roy Prieb as chief operating officer and chief financial officer;
Kleo Pharmaceuticals hired Joseph Grosso as chief scientific officer.
About the Author Reprints
